Replies to post #354365 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Kevindenver

to continue the thought, this will also add value the development and growth of a rare disease franchise with all indications initiated at phase 2/3.
© 2022 InvestorsHub.com, Inc.

WOW...has BP understood this yet? Looks like the entire process of trials/treating even Rare CNS diseases is resting on AVXL BioMarkers and ...dare we suggest...PREVENTION of CNS diseases w/BIO MARKER science controls validation.

[tredenwater2]

Bingo Kevin! We have a winner winner chicken dinner!

Plug n play with quick 14 week, biomarker driven rare disease trials. With excellent pre clinical validating a Ph 2b/3 trial(as we have already witnessed, major dot imo) and now mRNA expression as a biomarker, this may be a continuation or culmination of the “when you see what/how we did things you will then understand why” and the “front end is labor intensive but the back end will accelerate” quotes (paraphrased by me)!

The only question I have is does this mRNA biomarker help with Alzheimer’s readout to gain approval being how it is being validated?

PDD rolling great….bring on Alzheimer’s!

Tred